ImmunoPrecise

73 articles about ImmunoPrecise

• ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020

  8/31/2020

  Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2

• ImmunoPrecise to Present at The LD 500 Virtual Investor Conference

  8/31/2020

  IMMUNOPRECISE ANTIBODIES LTD. today announced that CEO Jennifer Bath will present to investors attending the LD 500 investor conference on Friday, September 4, 2020 at 1:00pm EST.

• IPA's Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization

  7/31/2020

   IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to announce that additional characterization of a subset of fully human, therapeutic antibodies, already shown to have potent neutralizing activity, ar

• IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

  6/29/2020

  IPA Announces  Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology

• ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)

  6/4/2020

  IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement dated May 14, 2020 , in a multi-company effort with the laboratory of Dr. Fr

• NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses

  5/27/2020

  IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria ("UVic")-based laboratory of Dr. Alexandre Brolo , experts in the development of novel diagnostic too

• ImmunoPrecise Announces Agreement with Janssen

  4/14/2020

  IMMUNOPRECISE ANTIBODIES LTD., a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement with Janssen Research & Development, LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.

• ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

  9/24/2019

  Entered into an LOI to form a Joint Venture as it partners in the continued development of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx, a clinical-stage biopharma company. AgonOx specializes in identifying and developing immuno-oncology therapeutics.

• ImmunoPrecise Acquires ModiQuest Research BV

  4/6/2018

  Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery

• 

  ImmunoPrecise Brings on New CEO

  2/9/2018

  ImmunoPrecise announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February 21, 2018.

• ImmunoPrecise Adds Scientific Depth to its Board of Directors

  12/20/2017

  ImmunoPrecise is pleased to announce the appointment of Dr. Robert Burke to the Company's Board of Directors. 

• ImmunoPrecise to Acquire ModiQuest Research BV

  12/7/2017

  The Transaction continues to realize on the Board's commitment to grow globally through strategic acquisitions.

• ImmunoPrecise Begins Humanized Antibody Development

  4/11/2017